Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)

Kazunobu Yamauchi, Yoshifumi Tanahashi, Mitsuhiro Okada, Jitsuki Tsuzuki, Akihiko Sato, Kazunari Abe, Haruo Inagaki, Hirotaka Agetsuma, Ritsuo Hattori, Hideo Izawa

研究成果: Article査読

2 被引用数 (Scopus)


The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).

ジャーナルClinical therapeutics
出版ステータスPublished - 1995

All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬理学(医学)


「Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。